- Poster presentation
- Open Access
Plasma antibodies that cross react to subtype-B and C third variable (V3) region develop in Indian HIV-1 infected iIndividuals with time
© Andrabi et al; licensee BioMed Central Ltd. 2012
- Published: 13 September 2012
- Plasma Viral Load
- Relative Binding
- Naive Patient
- Good Proportion
- Drug Naive Patient
Subtype-C alone accounts for approximately 50% of global and more than 95% human immunodeficiency virus-1(HIV-1) infection in India. Identification of antigenic epitopes that induce antibodies with cross-clade activity will be crucial to address the HIV-1viral diversity.
80 HIV-1 infected drug naive patients were recruited for this study. The study was approved by the institute ethics committee and informed consent was obtained from all the participants. The relative binding of anti-V3 polyclonal plasma antibodies to 35 mer consensus¬-B and C V3 peptides was done by ELISA binding assay. Statistical analysis was performed by Graphpad Prism 5.
Assessment of the relative binding revealed that 86% (69/80) of the plasma were able to reach an IC50 binding titer with consensus-B V3 peptide with substantially low antibody titers compared to binding with consensus-C V3 (mean IC50 V3-C=12611 versus V3-B=2736) (p<0.0001), implying that although majority of the antibodies were subtype specific, a good proportion of cross reactive anti-V3 antibodies also exist in these plasma (range=1-97%, mean=23%). We observed a strong correlation between percent cross reactive anti-V3 antibodies and days from first diagnosis (n=80: r=0.29 p=0.008) while no such association was found with other clinical and immunological parameters like plasma viral load (n=53: r=0.16 p=0.24), CD4 count (n=80: r=0.10 p=0.34), total plasma IgG levels (n=65: r=-0.09 p=0.45) and eventually with the V3 sequence of donor viruses.
This is the first study to demonstrate the presence of cross-clade reactive anti-V3 antibodies and their association with time in the plasma of HIV-1 infected Asian Indians from north India.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.